Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiometry | 17 | 2023 | 980 | 2.220 |
Why?
|
| Photons | 11 | 2023 | 507 | 1.800 |
Why?
|
| Radiotherapy, Conformal | 16 | 2021 | 902 | 1.310 |
Why?
|
| Radiotherapy Dosage | 32 | 2023 | 3842 | 1.160 |
Why?
|
| Film Dosimetry | 5 | 2022 | 59 | 0.990 |
Why?
|
| Electrons | 2 | 2023 | 168 | 0.900 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 24 | 2023 | 2370 | 0.890 |
Why?
|
| Lenses | 1 | 2021 | 14 | 0.830 |
Why?
|
| Phantoms, Imaging | 14 | 2021 | 1271 | 0.800 |
Why?
|
| Monte Carlo Method | 13 | 2023 | 671 | 0.770 |
Why?
|
| Breast | 5 | 2014 | 1344 | 0.760 |
Why?
|
| Radiotherapy, Intensity-Modulated | 15 | 2014 | 2104 | 0.690 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2009 | 388 | 0.640 |
Why?
|
| Organs at Risk | 6 | 2016 | 514 | 0.640 |
Why?
|
| Hodgkin Disease | 4 | 2014 | 1429 | 0.550 |
Why?
|
| Neutrons | 7 | 2009 | 117 | 0.470 |
Why?
|
| Gold | 3 | 2009 | 270 | 0.400 |
Why?
|
| Thermoluminescent Dosimetry | 3 | 2007 | 77 | 0.390 |
Why?
|
| Indium | 1 | 2009 | 20 | 0.370 |
Why?
|
| Dose-Response Relationship, Radiation | 10 | 2014 | 726 | 0.370 |
Why?
|
| Equipment Design | 6 | 2021 | 1204 | 0.360 |
Why?
|
| Algorithms | 13 | 2016 | 3890 | 0.350 |
Why?
|
| Radiation Dosage | 8 | 2013 | 1014 | 0.350 |
Why?
|
| Uncertainty | 3 | 2018 | 320 | 0.350 |
Why?
|
| Computer Simulation | 8 | 2023 | 1529 | 0.340 |
Why?
|
| Heart | 4 | 2014 | 1223 | 0.340 |
Why?
|
| Portal System | 1 | 2008 | 34 | 0.330 |
Why?
|
| Patient Positioning | 1 | 2010 | 195 | 0.320 |
Why?
|
| Breast Neoplasms | 13 | 2022 | 15694 | 0.310 |
Why?
|
| Prostheses and Implants | 1 | 2009 | 295 | 0.290 |
Why?
|
| Radiation Oncology | 3 | 2022 | 529 | 0.270 |
Why?
|
| Radiation Injuries | 3 | 2013 | 1411 | 0.270 |
Why?
|
| Particle Accelerators | 7 | 2010 | 352 | 0.260 |
Why?
|
| Scattering, Radiation | 8 | 2016 | 316 | 0.260 |
Why?
|
| Brachytherapy | 4 | 2016 | 977 | 0.260 |
Why?
|
| Models, Biological | 4 | 2011 | 3254 | 0.260 |
Why?
|
| Calibration | 4 | 2022 | 337 | 0.240 |
Why?
|
| Nanotubes, Carbon | 1 | 2023 | 29 | 0.240 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2013 | 1833 | 0.240 |
Why?
|
| Fetus | 1 | 2007 | 601 | 0.230 |
Why?
|
| Software | 8 | 2023 | 1321 | 0.210 |
Why?
|
| Water | 3 | 2022 | 361 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2018 | 7551 | 0.210 |
Why?
|
| Prostatic Neoplasms | 9 | 2009 | 5767 | 0.210 |
Why?
|
| Movement | 5 | 2011 | 556 | 0.200 |
Why?
|
| Radiography | 7 | 2023 | 1904 | 0.200 |
Why?
|
| Endometrial Neoplasms | 4 | 2013 | 1341 | 0.200 |
Why?
|
| Micronucleus Tests | 1 | 2000 | 20 | 0.190 |
Why?
|
| Lymphatic Irradiation | 3 | 2013 | 133 | 0.190 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2000 | 34 | 0.190 |
Why?
|
| Equipment Failure Analysis | 4 | 2009 | 329 | 0.180 |
Why?
|
| Reproducibility of Results | 9 | 2016 | 6009 | 0.180 |
Why?
|
| Iridium Radioisotopes | 2 | 2010 | 56 | 0.180 |
Why?
|
| Sensitivity and Specificity | 6 | 2016 | 4971 | 0.170 |
Why?
|
| Urinary Bladder | 6 | 2013 | 575 | 0.170 |
Why?
|
| Rectum | 6 | 2012 | 467 | 0.170 |
Why?
|
| Models, Statistical | 4 | 2016 | 1171 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2007 | 6869 | 0.160 |
Why?
|
| Radiotherapy, High-Energy | 4 | 2009 | 295 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 1648 | 0.150 |
Why?
|
| Humans | 55 | 2022 | 261506 | 0.150 |
Why?
|
| Vagina | 4 | 2013 | 317 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2403 | 0.140 |
Why?
|
| Printing, Three-Dimensional | 1 | 2018 | 129 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2000 | 1234 | 0.130 |
Why?
|
| Clavicle | 2 | 2010 | 65 | 0.110 |
Why?
|
| Pelvic Bones | 1 | 2013 | 95 | 0.110 |
Why?
|
| Jaw | 1 | 2012 | 20 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2000 | 1202 | 0.110 |
Why?
|
| Inhalation | 1 | 2011 | 42 | 0.100 |
Why?
|
| Veterans | 1 | 2022 | 1641 | 0.100 |
Why?
|
| Female | 26 | 2016 | 141928 | 0.100 |
Why?
|
| Intestine, Small | 3 | 2013 | 499 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 423 | 0.090 |
Why?
|
| Relative Biological Effectiveness | 2 | 2010 | 219 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 291 | 0.090 |
Why?
|
| Sulfones | 1 | 2010 | 143 | 0.080 |
Why?
|
| Lung | 4 | 2014 | 3151 | 0.080 |
Why?
|
| Thoracic Neoplasms | 1 | 2012 | 337 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 223 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2011 | 598 | 0.080 |
Why?
|
| Metal Nanoparticles | 1 | 2009 | 164 | 0.080 |
Why?
|
| Body Burden | 1 | 2007 | 65 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2013 | 2358 | 0.070 |
Why?
|
| Cisplatin | 3 | 2013 | 2432 | 0.070 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2005 | 126 | 0.070 |
Why?
|
| Cervix Uteri | 1 | 2008 | 253 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2011 | 665 | 0.070 |
Why?
|
| Combined Modality Therapy | 7 | 2013 | 8865 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 11538 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 756 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 5319 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2009 | 785 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2013 | 2292 | 0.060 |
Why?
|
| Postoperative Care | 3 | 2013 | 739 | 0.060 |
Why?
|
| Proton Therapy | 2 | 2013 | 1577 | 0.060 |
Why?
|
| Gamma Rays | 2 | 2005 | 242 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2012 | 3976 | 0.060 |
Why?
|
| X-Rays | 1 | 2023 | 146 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2023 | 232 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2005 | 285 | 0.050 |
Why?
|
| Urethra | 2 | 2010 | 144 | 0.050 |
Why?
|
| Quality Control | 3 | 2009 | 457 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 1162 | 0.050 |
Why?
|
| Male | 15 | 2022 | 123000 | 0.050 |
Why?
|
| Femur Head | 2 | 2012 | 41 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 585 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2002 | 1944 | 0.040 |
Why?
|
| Anal Canal | 1 | 2000 | 238 | 0.040 |
Why?
|
| Hysterectomy | 3 | 2010 | 611 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2022 | 348 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 2003 | 470 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 978 | 0.040 |
Why?
|
| Mesothelioma | 1 | 2003 | 544 | 0.040 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.040 |
Why?
|
| Filtration | 2 | 2007 | 92 | 0.040 |
Why?
|
| Neoplasms | 3 | 2009 | 15193 | 0.040 |
Why?
|
| Time Factors | 5 | 2013 | 12926 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 13658 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 671 | 0.040 |
Why?
|
| Vinblastine | 2 | 2011 | 453 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 1350 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 15862 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2001 | 889 | 0.040 |
Why?
|
| Axilla | 2 | 2009 | 902 | 0.030 |
Why?
|
| Retrospective Studies | 7 | 2012 | 37905 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2002 | 9180 | 0.030 |
Why?
|
| Polystyrenes | 2 | 2005 | 32 | 0.030 |
Why?
|
| Ions | 2 | 2005 | 53 | 0.030 |
Why?
|
| Young Adult | 2 | 2011 | 21445 | 0.030 |
Why?
|
| Intestines | 2 | 2012 | 686 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2000 | 1299 | 0.030 |
Why?
|
| Risk Factors | 2 | 2011 | 17523 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2005 | 665 | 0.030 |
Why?
|
| Aged | 6 | 2013 | 70117 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 5637 | 0.030 |
Why?
|
| Software Validation | 1 | 2011 | 32 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2013 | 277 | 0.020 |
Why?
|
| Pelvis | 1 | 2013 | 362 | 0.020 |
Why?
|
| Drinking Water | 1 | 2010 | 21 | 0.020 |
Why?
|
| Treatment Outcome | 5 | 2016 | 32848 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 363 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2005 | 2307 | 0.020 |
Why?
|
| Protective Devices | 1 | 2010 | 21 | 0.020 |
Why?
|
| Tungsten | 1 | 2010 | 17 | 0.020 |
Why?
|
| Bleomycin | 1 | 2011 | 467 | 0.020 |
Why?
|
| Fiducial Markers | 1 | 2010 | 96 | 0.020 |
Why?
|
| Air | 1 | 2010 | 63 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2009 | 2803 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 1546 | 0.020 |
Why?
|
| Middle Aged | 7 | 2013 | 86204 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2009 | 2203 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2011 | 485 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 4844 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 690 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2010 | 271 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 180 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 482 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 3168 | 0.020 |
Why?
|
| Respiration | 1 | 2010 | 447 | 0.020 |
Why?
|
| Physical Phenomena | 1 | 2007 | 20 | 0.020 |
Why?
|
| Physics | 1 | 2007 | 44 | 0.020 |
Why?
|
| Adult | 5 | 2013 | 77950 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2013 | 12873 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2010 | 619 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 2231 | 0.020 |
Why?
|
| X-Ray Film | 1 | 2005 | 31 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2007 | 244 | 0.020 |
Why?
|
| Semiconductors | 1 | 2005 | 22 | 0.020 |
Why?
|
| Californium | 1 | 1984 | 4 | 0.020 |
Why?
|
| Telemetry | 1 | 2005 | 39 | 0.020 |
Why?
|
| Cobalt Radioisotopes | 1 | 2005 | 42 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.020 |
Why?
|
| Radio Waves | 1 | 2005 | 25 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 1259 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 418 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 1987 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 3005 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 1972 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 355 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1984 | 629 | 0.010 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2004 | 88 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2005 | 699 | 0.010 |
Why?
|
| Normal Distribution | 1 | 2003 | 61 | 0.010 |
Why?
|
| Melanoma | 1 | 2001 | 5317 | 0.010 |
Why?
|
| Temperature | 1 | 2005 | 506 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2005 | 355 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 383 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 14289 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 665 | 0.010 |
Why?
|
| Stomach | 1 | 2005 | 387 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2005 | 604 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1984 | 702 | 0.010 |
Why?
|
| Esophagus | 1 | 2005 | 553 | 0.010 |
Why?
|
| Colon | 1 | 2005 | 670 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 1959 | 0.010 |
Why?
|
| Carboplatin | 1 | 2002 | 823 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 10035 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9244 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 925 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2009 | 2967 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2003 | 831 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 14889 | 0.010 |
Why?
|
| Proteins | 1 | 1984 | 1963 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 21713 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2002 | 1996 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 2961 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2002 | 1824 | 0.010 |
Why?
|
| Methods | 1 | 1993 | 189 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 29902 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 31252 | 0.010 |
Why?
|
| Child | 1 | 2012 | 29154 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 59536 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 7702 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1984 | 568 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1984 | 548 | 0.000 |
Why?
|
| Swine | 1 | 1984 | 1541 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 1454 | 0.000 |
Why?
|